Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
1.080
+0.030 (2.86%)
At close: May 12, 2025, 4:00 PM
1.040
-0.040 (-3.70%)
After-hours: May 12, 2025, 7:58 PM EDT
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$1,280,176
Market Cap
15.12M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MBRX News
- 15 hours ago - Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial - GlobeNewsWire
- 5 days ago - Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - GlobeNewsWire
- 6 days ago - Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin - GlobeNewsWire
- 7 days ago - Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents - GlobeNewsWire
- 13 days ago - Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer - GlobeNewsWire
- 25 days ago - Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire
- 5 weeks ago - Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewsWire
- 7 weeks ago - Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript - Seeking Alpha